- Home
- PBYI vs GECC Comparison
PBYI vs GECC Comparison
Compare PBYI & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBYI | GECC |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 107.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | GECC |
|---|---|---|
| Price | $5.82 | $7.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 389.6K | 86.4K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 19.87% |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | $46,553,000.00 |
| Revenue This Year | N/A | $32.16 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | $7.80 | ★ N/A |
| Revenue Growth | N/A | ★ 17.68 |
| 52 Week Low | $2.58 | $7.18 |
| 52 Week High | $6.12 | $11.46 |
Technical Indicators
Market Signals| Indicator | PBYI | GECC |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 47.78 |
| Support Level | $4.84 | $7.57 |
| Resistance Level | $5.11 | $7.80 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 99.01 | 56.14 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.